… panel of 8 proteins that can be measured in the blood that together distinguish people who have Parkinson’s Disease vs. … findings into a clinically-available tool.   Final Outcome    … Access to Data and Biospecimens …

… One of MJFF’s priorities is to develop a therapy to address the challenges in how levodopa, the gold standard therapy for Parkinson’s … progress in work addressing this challenge, and one such company, Impax Pharmaceuticals, is especially close to …

… drugs and impulse control disorders (ICDs)— syndromes of compulsive gambling, hypersexuality and excessive shopping, to name a few. This relationship has been known for many … habits. “The medical community does not appreciate how common these problems are and how serious they may be” …

… The Michael J. Fox Foundation is passing the podcast mic to our friends at the PD Avengers , a global alliance of … for a deep dive on what differentiates their mission and how people and families with PD can get involved today. … transcript of this podcast.  Allison Boiles Vice President Communications …

… NEWYORK, NY— The Michael J. Fox Foundation today announced $2 million in grants awarded under the third … executive officer of MJFF. In keeping with the Foundation’s commitment to keep highly promising research moving forward … under the 2007 initiative are extensions of projects that showed distinct promise when they were funded in earlier …

… of people and currently has no treatment that can slow or stop its progression. While large genetic and molecular … “druggability” of these PD-related target genes — that is, how likely they are to respond to medicines without harmful … real-world therapeutic development. Study Design: We will combine multi-omics data from human brain tissue to identify …